Immunovaccine Inc. (TSX VENTURE:IMV), a clinical stage vaccine
development company focused on advancing its patented DepoVax? vaccine
adjuvanting platform and product candidates, today announced that it
has entered into a research collaboration with one of the world's
leading animal health companies to develop next generation companion
animal vaccines. Under terms of the collaboration, Immunovaccine will
combine multiple vaccine candidates provided by its research partner
with the company's proprietary DepoVax adjuvanting vaccine technology.
The resulting vaccine products, which are expected to deliver
long-lasting, single-dose protection against several of the most
common infectious diseases effecting dogs and cats, will then be
advanced through veterinary studies in several indications by
Immunovaccine's research partner.
DepoVax is a vaccine adjuvanting platform that has been demonstrated
to work effectively with a broad range of antigens. Once administered,
vaccine products that feature the technology create a unique depot
effect that attracts antigen-presenting cells to generate a rapid and
robust immune response. As a result, the next generation vaccine
candidates developed through this new collaboration have the potential
to drive a new standard of care in the vaccination of pets including
dogs and cats, offering the necessary protection in just a single
"This partnership is the latest development to highlight the
significant promise our DepoVax technology holds for delivering more
rapid, stronger and longer-lasting vaccines," said John Trizzino,
chief executive officer of Immunovaccine. "This extension of our
animal health partnering strategy also supports the advancement of our
work in human health by providing additional data regarding the immune
system response to a broader range of infectious disease agents."
In addition to animal health, Immunovaccine is also developing human
health vaccines for cancer therapy and infectious disease using the
DepoVax technology platform. The company has two therapeutic cancer
vaccines in clinical development; DPX-Survivac for ovarian cancer and
DPX-0907 for breast, ovarian, and prostate cancer, and has advanced
several candidates in infectious disease and biodefense through the
National Institutes of Health and other partnerships.
Today's agreement represents an expansion of Immunovaccine's
partnerships in animal health. The company's additional partnerships
in the area of animal health include its ongoing collaboration with
Pfizer Animal Health, which is focused on leveraging the DepoVax
technology to create advanced vaccines against infectious diseases for
multiple livestock indications.
There are currently more than 72 million pet dogs and 82 million pet
cats in U.S. households, according to the American Veterinary Medical
Association. There is a growing global demand for premium companion
animal vaccines that can be safely and easily administered. According
to a Global Industry Analysts report, the veterinary vaccine market is
projected to reach US$ 5.6 Billion by 2015. Growth in this market is
driven by an increasing number of pet owners demanding products that
enhance the health and well-being of their pets.
In additional corporate news, Immunovaccine has retained Vida
Communication to provide strategic public relations and investor
relations services, effective May 9, 2012. Under the terms of the
agreement, Immunovaccine will pay Vida Communication a monthly fee of
$10,000 for select strategic communication services. The initial
contract term is 12 months and commences immediately. Neither Vida
Communication nor any of its principals have an ownership interest,
directly or indirectly, in Immunovaccine or its securities, nor has
the company granted Vida Communication or its principals any rights to
acquire any such interests.
Immunovaccine Inc. develops vaccines formulated in its vaccine
delivery platform for cancer therapy and infectious disease. The
company's DepoVax? platform is a patented lipid delivery system that
presents antigens plus adjuvant to the immune system for a prolonged
period and has the potential to enhance immune responses.
Immunovaccine has taken its platform technology and proprietary cancer
vaccine into Phase I human trials and has demonstrated its safety and
immunogenicity potential. The company is also capitalizing on the
broad potential of its delivery platform by creating new DepoVax-based
vaccines through multiple development collaborations. In addition to
the Company's human health vaccine strategy, it continues to capture
value from animal health vaccine applications. Pfizer Animal Health
has licensed the company's delivery technology platform to develop
vaccines for livestock. Connect at www.imvaccine.com or
This press release contains forward-looking information under
applicable securities law. All information that addresses activities
or developments that we expect to occur in the future is
forward-looking information. Forward-looking statements are based on
the estimates and opinions of management on the date the statements
are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ
materially from those set forth in this press release due to risks
affecting the Company, including access to capital, the successful
completion of clinical trials and receipt of all regulatory approvals.
Immunovaccine Inc. assumes no responsibility to update forward-looking
statements in this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.